Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 May;15(3):187-96.
doi: 10.1007/s10741-008-9094-x. Epub 2008 Apr 24.

Beta-blocker pharmacogenetics in heart failure

Jaekyu Shin  1 , Julie A Johnson
Affiliations
Review

Beta-blocker pharmacogenetics in heart failure

Jaekyu Shin et al. Heart Fail Rev. 2010 May.

Abstract

Beta-blockers (metoprolol, bisoprolol, and carvedilol) are a cornerstone of heart failure (HF) treatment. However, it is well recognized that responses to a beta-blocker are variable among patients with HF. Numerous studies now suggest that genetic polymorphisms may contribute to variability in responses to a beta-blocker, including left ventricular ejection fraction improvement, survival, and hospitalization due to HF exacerbation. This review summarizes the pharmacogenetic data for beta-blockers in patients with HF and discusses the potential implications of beta-blocker pharmacogenetics for HF patients.

PubMed Disclaimer

References

    1. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007–2018. - PubMed
    1. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547–1552. - PubMed
    1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) A randomised trial Lancet. 1999;353:9–13. - PubMed
    1. Reiter MJ. Cardiovascular drug class specificity: beta-blockers. Prog Cardiovasc Dis. 2004;47:11–33. - PubMed
    1. Hjalmarson A, Goldstein S, Fagerberg B, et al. MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF) JAMA. 2000;283:1295–1302. - PubMed

Publication types

MeSH terms

Substances